Similar articles

• The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells.

  Caillat-Zucman S, Blumenfeld N, Legendre C, Noel LH, Bach JF, Kreis H, Chatenoud L. Caillat-Zucman S, et al. Transplantation. 1990 Jan;49(1):156-60. Transplantation. 1990. PMID: 2137271
• Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.

  Henell KR, Bakke A, Kenny TA, Kimball JA, Barry JM, Norman DJ. Henell KR, et al. Transplant Proc. 1991 Feb;23(1 Pt 2):1070-1. Transplant Proc. 1991. PMID: 1824886 No abstract available.
• Prophylactic use of the new monoclonal antibody BMA 031 in clinical kidney transplantation.

  Smely S, Weschka M, Hillebrand G, Dendorfer U, Krombach F, Kurrle R, Land W, Hammer C. Smely S, et al. Transplant Proc. 1990 Aug;22(4):1785-6. Transplant Proc. 1990. PMID: 2143862 No abstract available.
• Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.

  Goldstein G. Goldstein G. Transplant Proc. 1987 Apr;19(2 Suppl 1):1-6. Transplant Proc. 1987. PMID: 3105134 Review. No abstract available.
• An overview of the use of the monoclonal antibody OKT3 in renal transplantation.

  Norman DJ. Norman DJ. Transplant Proc. 1988 Dec;20(6):1248-52. Transplant Proc. 1988. PMID: 2974204 Review.